MCRB insider transactions
Seres Therapeutics Inc. (MCRB) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for MCRB
- Officer Brady Kelly converted options into 180 shares and sold $444 worth of shares (59 units at $7.53), increasing direct ownership by 1% to 8,562 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Officer Henn Matthew R converted options into 238 shares and sold $580 worth of shares (77 units at $7.53) as part of a pre-agreed trading plan, increasing direct ownership by 2% to 7,838 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Director Shaff Eric D. converted options into 722 shares and sold $1,950 worth of shares (259 units at $7.53) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 12,040 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Officer Desrosier Thomas converted options into 244 shares and sold $595 worth of shares (79 units at $7.53) as part of a pre-agreed trading plan, increasing direct ownership by 2% to 7,954 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Seres Therapeutics Inc.4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- New insider Brady Kelly claimed ownership of 8,441 shares (SEC Form 3)3 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Officer Kender Richard N4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Officer Henn Matthew R4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Officer Thorell Marella4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Officer Desrosier Thomas4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Officer Young Teresa L. converted options into 231 shares and sold $635 worth of shares (75 units at $8.47), increasing direct ownership by 2% to 8,557 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Director Shaff Eric D. converted options into 723 shares and sold $2,194 worth of shares (259 units at $8.47), increasing direct ownership by 4% to 11,577 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Officer Henn Matthew R converted options into 239 shares and sold $754 worth of shares (89 units at $8.47), increasing direct ownership by 2% to 7,677 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Officer Desrosier Thomas converted options into 244 shares and sold $661 worth of shares (78 units at $8.47), increasing direct ownership by 2% to 7,789 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Officer Young Teresa L. converted options into 4,228 shares and sold $18,027 worth of shares (1,042 units at $17.30), increasing direct ownership by 61% to 8,401 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Director Shaff Eric D. converted options into 721 shares and sold $3,754 worth of shares (217 units at $17.30), increasing direct ownership by 5% to 11,113 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Officer Desrosier Thomas converted options into 244 shares and sold $1,315 worth of shares (76 units at $17.30), increasing direct ownership by 2% to 7,623 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Officer Henn Matthew R converted options into 4,236 shares and sold $21,746 worth of shares (1,257 units at $17.30), increasing direct ownership by 66% to 7,527 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Officer Young Teresa L.4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Officer Henn Matthew R4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Director Shaff Eric D. converted options into 724 shares and sold $3,613 worth of shares (217 units at $16.65), increasing direct ownership by 5% to 10,609 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Officer Desrosier Thomas converted options into 244 shares and sold $1,265 worth of shares (76 units at $16.65), increasing direct ownership by 2% to 7,455 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Officer Henn Matthew R converted options into 238 shares and sold $1,215 worth of shares (73 units at $16.65), increasing direct ownership by 4% to 4,548 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Officer Young Teresa L. converted options into 230 shares and sold $982 worth of shares (59 units at $16.65), increasing direct ownership by 3% to 5,215 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Director Rosiello Robert L.4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 3 filed by new insider Rosiello Robert L.3 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Director Ausiello Dennis A4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Director Berenson Stephen4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Director Fraser Claire4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Officer Young Teresa L. converted options into 231 shares and sold $459 worth of shares (63 units at $7.28), increasing direct ownership by 3% to 5,044 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- CEO and President Shaff Eric D. converted options into 721 shares and sold $1,602 worth of shares (220 units at $7.28), increasing direct ownership by 5% to 10,102 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Chief Legal Officer and EVP Desrosier Thomas converted options into 244 shares and sold $575 worth of shares (79 units at $7.28), increasing direct ownership by 2% to 7,287 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Officer Henn Matthew R converted options into 238 shares and sold $561 worth of shares (77 units at $7.28), increasing direct ownership by 4% to 4,383 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Director Graves Kurt4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Director Kender Richard N4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Director Dere Willard H4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Director Ausiello Dennis A4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Director Fraser Claire4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Director Berenson Stephen4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Director Biondi Paul4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Officer Young Teresa L. converted options into 10,470 shares and sold $2,704 worth of shares (3,338 units at $0.81), increasing direct ownership by 8% to 97,536 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Officer Henn Matthew R. converted options into 10,626 shares and sold $3,204 worth of shares (3,953 units at $0.81), increasing direct ownership by 9% to 84,443 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- CEO and President Shaff Eric D. converted options into 34,376 shares and sold $10,314 worth of shares (12,726 units at $0.81), increasing direct ownership by 13% to 192,039 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Chief Legal Officer and EVP Desrosier Thomas converted options into 11,564 shares and sold $3,485 worth of shares (4,300 units at $0.81), increasing direct ownership by 5% to 142,456 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Officer Von Moltke Lisa converted options into 11,876 shares and sold $3,579 worth of shares (4,416 units at $0.81), increasing direct ownership by 23% to 39,875 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Officer Thorell Marella4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by CEO and President Shaff Eric D.4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Chief Legal Officer and EVP Desrosier Thomas4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Officer Young Teresa L.4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Officer Von Moltke Lisa4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Officer Henn Matthew R.4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 4 filed by Director Woerle Hans-Juergen4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- SEC Form 3 filed by new insider Woerle Hans-Juergen3 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Chief Legal Officer and EVP Desrosier Thomas converted options into 2,656 shares and sold $475 worth of shares (878 units at $0.54), increasing direct ownership by 1% to 135,192 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Officer Von Moltke Lisa converted options into 2,969 shares and sold $528 worth of shares (977 units at $0.54), increasing direct ownership by 7% to 32,415 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Officer Henn Matthew R. converted options into 2,812 shares and sold $501 worth of shares (927 units at $0.54), increasing direct ownership by 2% to 77,770 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- CEO and President Shaff Eric D. converted options into 7,812 shares and sold $1,355 worth of shares (2,505 units at $0.54), increasing direct ownership by 3% to 170,389 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Officer Young Teresa L. sold $398 worth of shares (735 units at $0.54) and converted options into 2,656 shares, increasing direct ownership by 2% to 90,404 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Officer Von Moltke Lisa converted options into 13,744 shares and sold $2,991 worth of shares (4,334 units at $0.69), increasing direct ownership by 45% to 30,423 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
- Officer Henn Matthew R. converted options into 12,622 shares and sold $2,749 worth of shares (3,984 units at $0.69), increasing direct ownership by 13% to 75,885 units (SEC Form 4)4 - Seres Therapeutics, Inc. (0001609809) (Issuer)